Beta Bionics, Inc. (BBNX) Revenue History
Annual and quarterly revenue from 2022 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BBNX Revenue Growth
BBNX Revenue Analysis (2022–2025)
As of May 8, 2026, Beta Bionics, Inc. (BBNX) generated trailing twelve-month (TTM) revenue of $110.2 million, reflecting explosive growth of +56.6% year-over-year. The most recent quarter (Q1 2026) recorded $27.6 million in revenue, down 14.0% sequentially.
Looking at the longer-term picture, BBNX's historical revenue data shows a 3-year CAGR of +724.3%. The company achieved its highest annual revenue of $100.3 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including TNDM (-6.8% YoY), PODD (+31.9% YoY), and DXCM (+16.2% YoY), BBNX has outperformed the peer group in terms of revenue growth. Compare BBNX vs TNDM →
BBNX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BBNXCurrent | $110M | +56.6% | - | -71.5% | |
 TNDM | $1.0B | -6.8% | +15.3% | -7.7% | |
 PODD | $2.7B | +31.9% | +24.5% | 17.5% | |
 DXCM | $4.7B | +16.2% | +19.3% | 19.6% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% |
BBNX Historical Revenue Data (2022–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $100.3M | +53.9% | $55.5M | 55.4% | $-71,681,000 | -71.5% |
| 2024 | $65.1M | +442.9% | $35.9M | 55.1% | $-45,251,000 | -69.5% |
| 2023 | $12.0M | +6601.1% | $6.3M | 52.6% | $-35,850,000 | -298.9% |
| 2022 | $179K | - | $179K | 100.0% | $-65,844,000 | -36784.4% |
See BBNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BBNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBBNX — Frequently Asked Questions
Quick answers to the most common questions about buying BBNX stock.
Is BBNX's revenue growth accelerating or slowing?
BBNX revenue is accelerating at +56.6% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $110M. Growth momentum has increased versus prior periods.
What is BBNX's long-term revenue growth rate?
Beta Bionics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +56.6% is above this long-term average.
How is BBNX's revenue distributed by segment?
BBNX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2022-2025 are available for download. Segment mix reveals concentration and diversification trends.